Manufactured recombinant human GH (rhGH) has been available for more than 25 years. In the meantime, the GH produced by various manufacturers has been approved for application in replacement therapy in children and adults with GH deficiency or a number of disorders involving small stature in children. Until recently approval for each individual diagnosis was only granted after extensive studies on the long-term efficacy (e.g. adult height reached) and safety of the various products. Meanwhile, the European approving agency, the European Medicines Evaluation Agency (EMEA), has relinquished this restrictive stance. Thus, new rhGH preparations can count on gaining approval for existing indications even without conducting standard clinical studies of their efficacy and safety for each of these indications. The EMEA’s reconsideration is apparently based on the rationale that recombinant GH can, in effect, be considered equivalent to the tried and tested preparations in wide use, provided certain specifications are met. The term ‘biosimilars’ was coined to denote the similarities between the products rather than their parity, as is the case with generics for instance. The higher complexity of biopharmaceuticals relates not only to the substances themselves but also to the manufacturing process. It is generally believed that modifications to a manufacturing process – which are a prerequisite for a patent – may cause modifications of the active substance which then may lead to different long-term effects. Thus, the term ‘biosimilar’ does not indicate that complex biopharmaceuticals deriving from the same substance are entirely identical, nor does the approval of a ‘biosimilar’ ensure this. The factual information provided here is offered towards clarification of some uncertainties and as a contribution towards resolving open questions relating to the topic of biosimilars. The final choice of product to be prescribed must be made by the informed, independent physician.

Keywords:
Growth hormone, Biosimilars, Growth promotion, Treatment, growth hormone deficiency
1.
Baumann G: Growth hormone heterogeneity: genes, isohormones, variants, and binding protein. Endocr Rev 1991;12:424–449.
2.
Moseley CT, Phillips JA: Pituitary gene mutations and the growth hormone pathway. Semin Reprod Med 2000;18:21–29.
3.
Smith RG, van der Ploeg LHT, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ, Fisher MH, Nargund RP, Patchett AA: Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997;18:621–645.
4.
Kelly PA, Finidori J, Moulin S, Kedzia C, Binart N: Growth hormone receptor signalling and actions in bone growth. Horm Res 2001;55(suppl 1):14–17.
5.
Ranke MB, Elmlinger M: Functional role of insulin-like growth factor binding proteins. Horm Res 1997;48(suppl 4):9–15.
6.
Moeller N: The role of growth hormone in the regulation of human fuel metabolism; in Flyvbjerg A, Örskov H, Alberti KGMM (eds): Growth Hormone and Insulin-Like Growth Factor I. New York, Wiley, 1993, pp 77–108.
7.
Jorgensen JO, Vestergaard E, Gormsen L, Jessen N, Norrelund H, Christiansen JS, Moeller N: Metabolic consequences of GH deficiency. J Endocrinol Invest 2005;28 (suppl):47–51.
8.
Zabransky S, Ranke MB: Wachstumshormon in der Pädiatrie: Aktuelle und zukünftige Behandlungskonzepte. Mannheim, Palatium, 2002.
9.
Ranke MB: Growth hormone insufficiency: clinical features, diagnosis, and therapy; in DeGroot L (ed): Endocrinology, ed 3. Philadelphia, Saunders, 1994, pp 330–340.
10.
Wüster C, von zur Mühlen A, Ranke MB: Das Syndrom des Wachstumshormonmangels beim Erwachsenen. Dtsch Ärzteblatt 1994;91:B1795–B1796.
11.
Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Fraizier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, Melmed S, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA: Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995;80:1532–1540.
12.
Thorner MO, Bengtsson BA, Ho KY, Albertsson-Wikland K, Christiansen JS, Faglia G, Irie M, Jörgensen JOL, Ranke M, Rosenfeld R, Shalet S, Takano K, van der Veen EA, Weissberger A: The diagnosis of growth hormone deficiency in adults. J Clin Endocrinol Metab 1995;80:3097–3098.
13.
MB Ranke (ed): Diagnostics of Endocrine Function in Children and Adolescents, ed 3. Basel, Karger, 2003.
14.
de Boer H, van der Veen E: Guidelines for optimizing growth hormone replacement therapy in adults. Horm Res 1997;48(suppl 5):21–30.
15.
Thorner MO: Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868–1870.
16.
Bowlby DA, Rapaport R: Safety and efficacy of growth hormone therapy in childhood. Pediatr Endocrinol Rev 2004;2(suppl 1):68–71.
17.
Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA: Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. Lancet 2000;355:610–613.
18.
Tattersall R: A history of growth hormone. Horm Res 1996;46:236–247.
19.
Lindholm J: Growth hormone: historical notes. Pituitary 2006;9:5–10.
20.
Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901–903.
21.
Hunter WM, Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962;194:495–496.
22.
Stein J, Lester J, Fosten A, Shownkeen RC, Hartree AS: Studies of a human growth hormone preparation used for clinical treatment in Great Britain. J Endocrinol 1982;94:203–210.
23.
Holmström B, Fhölenhag K: Characterization of human growth hormone preparations used for the treatment of pituitary dwarfism: a comparison of currently used batches. J Clin Endocrinol Metab 1975;40:856–862.
24.
Bristow AF: International standards for growth hormone. Horm Res 1999;51 (suppl):7–12.
25.
Raiti S: The national hormone and pituitary program; in Raiti S, Tolman RA (eds): Human Growth Hormone. London, Plenum Press, 1986, pp 1–12.
26.
Trygstad O, Voss I: Preparation of purified human growth hormone and a crude human pituitary gonadotropin. Acta Endocrinol (Copenh) 1971;66:478–490.
27.
Jones RL, Benker G, Salacinski PR, Lloyd TJ, Lowry PJ: Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use. J Endocrinol 1979;82:77–86.
28.
Powell-Jackson J, Weller RO, Kennedy P, Preece MA, Whitcombe EM, Newsom-Davis J: Creutzfeldt-Jacob disease after administration of human growth hormone. Lancet 1985;2:244–246.
29.
Frazier SD: The not-so-good old days: working with pituitary growth hormone in North America, 1956 to 1985. J Pediatr 1997;131:1–4.
30.
Goujard J, Entat M, Maillard F, Mugnier E, Rappaport R, Job JC: Evaluation of risks related to human growth hormone (hGH) treatment. Results of an epidemiologic survey conducted in France of patients treated from 1959 to 1985. Arch Fr Pediatr 1989;46:411–416.
31.
Swerdlow AJ, Higgins CD, Adlard P, Jones ME, Preece MA: Creutzfeldt-Jacob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 2003;61:783–791.
32.
Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, Ross MJ, Miozzari G, Crea R, Seeburg PH: Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 1979;281:544–548.
33.
Flodh H: Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand 1986;325(suppl):1–9.
34.
Ross MJ, Olson KC, Geier MD, O’Connor JV, Jones JS: Recombinant DNA synthesis of human growth hormone; in Raiti S, Tolman RA (eds): Human Growth Hormone. London, Plenum Press, 1986, pp 241–256.
35.
Hizuka N, Hendricks CM, Pavlakis GN, Hamer DH, Gorden P: Properties of human growth hormone polypeptides: purified from pituitary extracts and synthesized in monkey kidney cells and bacteria. J Clin Endocrinol Metab 1982;55:545–550.
36.
Catzel D, Lavelski H, Marquis CP, Gray PP, Van Dyk D, Mahler SM: Purification of recombinant human growth hormone from CHO cell culture supernatant by Gradiflow preparative electrophoresis technology. Protein Expr Purif 2003;32:126–134.
37.
Gellerfors P, Eketorp G, Fhölenmhag K, Pavlu B, Johansson S, Fryklund L: Characterisation of a secreted form of recombinant derived human growth hormone, expressed in Escherichia coli cells. J Pharm Biomed Anal 1989;7:173–183.
38.
Ribela MT, Gout PW, Bartolini P: Synthesis and chromatographic purification of recombinant human pituitary hormone. J Chromatogr B Analyt Technol Biomed Life Sci 2003;760:285–316.
39.
Crommelin DJA: Differences between biopharmaceuticals and low-molecular-weight pharmaceuticals. Eur J Hosp Pharmacy 2003;1:74–76.
40.
De Palo EF, Gatti R, Antonelli G, Spinella P: Growth hormone isoforms, segments/fragments: does a link exist with multifunctionality? Clin Chim Acta 2006;364:77–81.
41.
Frost H: Antibody-mediated side effects of recombinant proteins. Toxicology 2005;209:155–160.
42.
Fryklund LM, Bierich JR, Ranke MB: Recombinant human growth hormone. Clin Endocrinol Metab 1986;15:511–535.
43.
Bierich JR, Ranke MB, Beyer P, Bittner P, Borkenstein H, Brämswig J, Butenandt O, Kollmann F, Stöver B, Schweikert HU: Therapie des hypophysären Zwergwuchses mit rekombinantem menschlichen Wachstumshormon. Eine Multizenterstudie. Dtsch Med Wochenschr 1986;111:483–489.
44.
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP): Concept Paper on Guideline on Immunogenicity Assessment of Therapeutic Proteins. www.emea.eu.int/pdfs/human/biosimilar/24651105en.pdf
45.
Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R: Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996;81:1704–1710.
46.
Wilton P: Adverse events during GH treatment: 10 years’ experience in KIGS; in Ranke MB, Wilton P (eds): Growth Hormone Therapy in KIGS – 10 Years Experience. Heidelberg, Barth, 1999, pp 349–364.
47.
Wyatt D: Lessons from the national cooperative growth study. Eur J Endocrinol 2004;151(suppl 1):55–59.
48.
Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, Lippe B: Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005;90:5502–5504.
49.
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP): Concept Paper on Guideline on Comparability of Biotechnology derived Medicinal Products after a Change in the Manufacturing Process: Non-clinical and Clinical Issues. EMEA/CHMP/BMWP/9437/2006/corr
50.
Omnitrope – European Public Assessment Report (EPAR): H/C/607. www.emea.eu. int/humandocs/PDFs/EPAR/Omnitrope/060706en1.pdf
51.
Lu AY: Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos 1998;26:1217–1222.
52.
Van Rijkom, Leufkens H, Crommelin D, Rutter F, Broekmens A: Assessment of biotechnology drugs: what are the issues. Health Policy 1999;47:255–274.
53.
Ronco C: Biosimilars: how similar are they? Int J Artif Organs 2005;28:552–553.
54.
Combe C, Tredree RL, Schellekens H: Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954–962.
55.
Crommelin DJA, Bermejo T, Bissig M, Damiaans J, Krämer I, Rambourg P, Sctoccaro G, Strukelj B, Tredree R: Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci 2005;11:11–17.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.